# Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Study · id `cardio:ct-nct02072330` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02072330](<https://clinicaltrials.gov/study/NCT02072330>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02072330

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

## Technical summary

Registry record NCT02072330. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 353 participants (enrolled count; ClinicalTrials.gov record NCT02072330, source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)
- Start date: 2013-03 (registry gives no type) (ClinicalTrials.gov record NCT02072330, source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT02072330, source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT02072330, source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02072330, source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02072330-2014-02-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
- Condition: Grade I or II Essential Hypertension
- Intervention (Drug): TAK-536CCB
- Intervention (Drug): TAK-536CCB + Hydrochlorothiazide
- Intervention (Drug): Hydrochlorothiazide
- Intervention (Drug): Hydrochlorothiazide
- Intervention (Drug): TAK-536CCB + Hydrochlorothiazide
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Hydrochlorothiazide (`cardio:hydrochlorothiazide`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: a2fbd9ac381af24c604733baf61d6b11ac7d3fdda8afd563282cb0ceb75a5dd0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
